$4M+
Case Outcomes
4
Biomarker Panel
100%
Cost Recoverable
6.4×
Avg. ROI
What We Do
Measure. Track. Document.
Measure
FDA-cleared blood biomarkers detect injury at the molecular level.
Track
Longitudinal monitoring captures severity, recovery, and progression.
Document
Audit-ready reports with chain-of-custody for any scrutiny.
Why It Matters
Without Biomarkers vs. With
Without Biomarkers
CT/MRI shows "normal"
Symptoms called subjective
Defense disputes injury
Recovery timeline unclear
Cases undervalued
With NWP Biomarkers
Molecular-level injury detected
Objective biologic signals
Evidence withstands Daubert
Tracked trajectory over time
150K–$2M+ uplift documented
Cross-Sector Applications
Where the Value Applies
The same evidence platform adapts to each sector's workflows, compliance requirements, and decision-making standards.
NWP
One Platform, Every Stakeholder
Select a sector or stakeholder to see how objective biomarker evidence applies to their specific workflows, compliance needs, and decision-making standards.
The outer ring represents the sectors we serve — from impact injury and defense to workplace safety, insurance, and litigation.
The inner ring represents who benefits — individuals seeking clarity and organizations building governance.
Core Biomarker Panel
Four Markers. One Report.
GFAP
Acute DetectionDetects glial injury. FDA-cleared.
NfL
ProgressionTracks axonal damage over time.
APOE
PrognosticGenetic risk for worse outcomes.
p-Tau217
Future RiskLinks injury to neurodegeneration.
Hours post-injuryDays to monthsLifetime genetic contextLong-term trajectory
Who We Serve
Find Your Use Case
Ready to See the Evidence?
Schedule a briefing to learn how biomarker evidence can support your work.
